Altimmune, Inc. expected to post a loss of 13 cents a share - Earnings Preview

Altimmune

10/11/2026 14:03

Altimmune, Inc. ALT.OQ ALT.O is expected to  show a fall in quarterly revenue when it reports  results on November 12 for the period ending September 30 2026

​LSEG's mean analyst estimate for Altimmune, Inc. is for a loss of 13 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Altimmune, Inc. is $15.00, about 607.5% above its last closing price of $2.12
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Jun. 30 2026
-0.14
-0.14
-0.12
Beat
13.4
Mar. 31 2026
-0.25
-0.25
-0.18
Beat
26.6
Dec. 31 2025
-0.24
-0.24
-0.27
Missed
-11.3​
Sep. 30 2025
-0.28
-0.28
-0.21
Beat
25.4
​​Jun. 30 2025
-0.33
-0.32
-0.27
Beat
16.4
Mar. 31 2025
-0.37
-0.36
-0.26
Beat
28.4​
Dec. 31 2024
-0.34
-0.33
-0.33
Met
-0.8
Sep. 30 2024
-0.38
-0.35
-0.32
Beat
9.6
This summary was machine generated November 10 at 14:03 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)